^
Association details:
| Biomarker: | KRAS G12V |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations
Published date:
09/24/2020
Excerpt:
A 66-year-old woman of Chinese ethnicity...thus establishing stage IVB lung adenocarcinoma….Tis-sue biopsy while on osimertinib therapy confirmed the pres-ence of the original EGFR mutation profile along with theKRAS-G12V mutation, confirming the latter as the mechanismof resistance to EGFR-targeted therapy.
DOI:
10.1002/onco.13537
